Business Wire

MA-VERTEX

Share
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsive to the vanza triple. Vertex used a priority review voucher for this submission reducing the review time from 10 months to 6 months, resulting in a Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025.

“The FDA acceptance of our vanza triple application and the MAA validation by the EMA represent important milestones in the decades-long development of CFTR modulators and another example of our track record of serial innovation in CF,” said Nia Tatsis, Ph.D., Executive Vice President, Chief Regulatory and Quality Officer at Vertex. “Vanzacaftor raises the high bar set by TRIKAFTA® and gives more people with CF the chance to get to levels of sweat chloride below the diagnostic threshold for CF, and even to levels of sweat chloride seen in those without CF.”

Vertex also received validation of its Marketing Authorization Application (MAA) submission by the European Medicines Agency (EMA) in the EU for patients ages 6 years and older. The company has also submitted in Canada, Australia, Switzerland and the U.K.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 92,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the 30s, but with treatment, projected survival is improving.

Today Vertex CF medicines are treating over 65,000 people with CF across 60 countries on six continents. This represents 2/3 of the diagnosed people with CF eligible for CFTR modulator therapy.

Diagnosis of CF is often made by genetic testing and is confirmed by testing sweat chloride (SwCl), which measures CFTR protein dysfunction. The diagnostic threshold for CF is SwCl ≥60 mmol/L, while levels between 30-59 indicate CF is possible and more testing may be needed to make the diagnosis of CF. A SwCl level of <30 mmol/L is seen in people who carry one copy of a CFTR gene mutation but do not have any manifestation of disease (carriers). Higher levels of SwCl are associated with more severe disease. Restoring CFTR function leads to lower levels of SwCl. SwCl levels below 60 mmol/L are associated with improved outcomes such as better and more stable lung function, fewer pulmonary exacerbations, better quality of life and improved survival. Restoring SwCl levels below 30 mmol/L has long been the ultimate treatment goal for Vertex, as levels below 30 mmol/L are considered normal and are typical of CF carriers who do not have disease.

About vanzacaftor/tezacaftor/deutivacaftor (the “vanza triple”)

In people with CF, mutations in the CFTR gene lead to decreased quantity and/or function of the CFTR protein channel at the cell surface. Vanzacaftor and tezacaftor are designed to increase the amount of CFTR protein at the cell surface by facilitating the processing and trafficking of the CFTR protein. Deutivacaftor is a potentiator designed to increase the channel open probability of the CFTR protein delivered to the cell surface to improve the flow of salt and water across the cell membrane.

Investigational vanzacaftor/tezacaftor/deutivacaftor was granted Fast Track and Orphan Drug Designations from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

The vanza triple will be subject to a meaningfully lower single-digit royalty obligation, compared to the rate payable on Vertex’s current CF portfolio.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Nia Tatsis, Ph.D., in this press release, and statements regarding our expectations for the benefits of and potential for the vanza triple, and our expectations that the vanza triple will be subject to a lower single-digit royalty obligation. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, that future competitive or other market factors may adversely affect the commercial potential for the vanza triple, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240702676594/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Settles Pending Litigation13.2.2025 13:00:00 CET | Press release

Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain orchestration, has entered into a settlement agreement with Blue Yonder Group, Inc. to fully resolve all pending litigation matters between the companies which includes Blue Yonder’s patent infringement claims and Kinaxis’ trade secret misappropriation counterclaims. The terms of the settlement agreement are confidential. About Kinaxis Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please

Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts13.2.2025 13:00:00 CET | Press release

Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership. Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India. Flowc

Infobip Joins EU Initiative to Boost Europe's Global Competitiveness13.2.2025 12:47:00 CET | Press release

Global cloud communications platform Infobip has officially signed the contract to join the IPCEI-CIS project, an EU-led initiative to create the next-generation global communications platform to increase Europe's international competitiveness. The signing took place at Infobip's campus in Zagreb, where Croatian Prime Minister Andrej Plenković participated in the event alongside Infobip's CEO Silvio Kutić. With this project, Europe aims to safeguard its digital and technological sovereignty, as many existing models that dominate the cloud infrastructure sector do not often align with EU data protection and transparency regulations. Croatian Prime Minister Andrej Plenković said: "Infobip is an example of Croatian technological excellence and global success. Its entry into the Project of Common European Interest (IPCEI) confirms its key role in European digital infrastructure. This project helps create a secure cloud infrastructure, supporting industries, companies, and public services a

Ricardo Signs Deal to Support Singer With Bespoke Manual Transmissions13.2.2025 10:00:00 CET | Press release

Ricardo has signed a multi-year deal to supply transmissions for Porsche 911s reimagined by Singer Ricardo, a global strategic, environmental, and engineering consulting company, has signed a deal to supply bespoke, manual transmissions to Singer’s operations in the US and UK. The transmissions will be exclusive to Singer and will initially be available to owners who request Singer’s Classic Turbo or DLS Turbo restoration services for their Type 964 Porsche 911. Singer arrived on the automotive scene with their Classic services in 2009. Since then, the company has developed restoration services allowing owners to personalise both naturally aspirated and turbocharged cars. A Porsche 911 Reimagined by Singer is a rare machine, bringing together iconic design with twenty-first century engineering and material science. Ricardo’s design team will ensure that the transmissions meets the exacting, high performance needs of Singer’s clients. The focus is on delivering an H-pattern transmission

Xsolla Partners With Day of the Devs for 2025 to Support New Game Development and Launches at Key Events13.2.2025 10:00:00 CET | Press release

Day Of The Devs Powered By Xsolla Will Celebrate Creativity And Bring Opportunities Together For Game Developers Of All Genres, Backgrounds, And Locations Xsolla, a leading global video game commerce company, announces its 2025 flagship sponsorship for Day of the Devs, a non-profit organization celebrating video games' creativity, diversity, and magic. This announcement underscores Xsolla's commitment to empowering game developers and bringing together opportunities for creative talent and development worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213515388/en/ (Graphic: Xsolla) “This partnership and collaboration underscores our ongoing mission to empower developers and make great games more accessible worldwide no matter what size or where they are from,” said Berkley Egenes, Chief Marketing & Growth Officer. “Day of the Devs powered by Xsolla provides an unparalleled platform to support diverse talent and cr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye